14-Sep-2018 | Zion Market Research
Zion Market Research has published a new report titled “Thrombosis Drug Market by Drug Class (Factor Xa Inhibitor, Low Molecular Weight Heparin, and P2Y12 Platelet Inhibitor), by Indications (Pulmonary Embolism, Atrial Fibrillation, and Deep Vein Thrombosis), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017- 2024”. According to the report, global thrombosis drug market was valued at approximately 19842.26 million in 2017 and is expected to generate revenue of around USD 40934.75 million by end of 2024, growing at a CAGR of around 9.3% between 2018 and 2024.
Thrombosis is a blood clot in the veins or arteries obstructing the blood flow in the circulatory system. It may be formed due to injury or some other reasons. Anticoagulant and blood thinners are the basic treatment options available for the treatment of thrombosis such as Heparin, warfarin, and others. When blood clots form inside the blood vessel and it travels around the body it is known as an embolus. This condition is considered as life-threatening as it may lead to stroke, myocardial infarction, ischemia, and others. In arterial thrombosis, surgery is required as it may lead to acute limb ischemia and obstructs the blood flow in the limbs.
Browse the full "Thrombosis Drug Market by Drug Class (Factor Xa Inhibitor, Low Molecular Weight Heparin, and P2Y12 Platelet Inhibitor), by Indications (Pulmonary Embolism, Atrial Fibrillation, and Deep Vein Thrombosis), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017- 2024" report at https://www.zionmarketresearch.com/report/thrombosis-drug-market
Thrombosis drug market is mainly driven by the increased prevalence of thrombosis due to the various changes in the lifestyle which may cause thrombosis. As per the Centers for Disease Control and Prevention report, there were around 900,000 people affected by deep vein thrombosis or pulmonary embolism, i.e., 1 to 2 per thousand people every year in the U.S. are affected. There are various new drugs available in the market which provides better and effective treatment for the thrombosis which is also expected to support the growth of thrombosis drug market over the forecast period. Furthermore, increased awareness among people and major market players are also focusing on the development of better, effective, and new medicines to provide advanced healthcare facilities to the patients. However, unmet patient needs and untapped market are expected to create several opportunities in the thrombosis drug market. Moreover, increased use of generics drugs is expected to inhibit the growth of thrombosis drug market over the forecast period.
The thrombosis drug market is segmented on the basis of drug class such as Factor Xa Inhibitor, Low Molecular Weight Heparin, and P2Y12 Platelet Inhibitor. Factor Xa Inhibitor segment is expected to dominate the thrombosis drug market over the forecast period. Based on the indication, the thrombosis drug market is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. Pulmonary embolism is expected to dominate the thrombosis drug market in the near future. Based on the distribution channel, the thrombosis drug market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Over the forecast period, hospital pharmacies are expected to dominate the thrombosis drug market.
Based on regions, the global thrombosis drug market is fragmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to contribute major market share over the forecast period owing to the advanced healthcare infrastructure and facilities. Europe is expected to closely follow North America in terms of growth. The Asia Pacific is expected to experience a rapid growth over the forecast period. Latin America and the Middle East & Africa are expected to experience a considerable growth over the forecast period.
Some of the key players in the thrombosis drug market include GlaxoSmithKline Plc., Aspen Pharmacare Holdings Limited, Johnson & Johnson, Sanofi, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Baxter International Inc., and Pfizer, Inc., among others.
This report segments the global thrombosis drug market as follows:
Global Thrombosis Drug Market: Drug Type Segment Analysis
Global Thrombosis Drug Market: Indication Segment Analysis
Global Thrombosis Drug Market: Distribution Channel Segment Analysis
Global Thrombosis Drug Market: Regional Segment Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651